Tyra Biosciences, INC Form 4 insider transactions

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, acquired 115,000 stock options on August 14, 2024, at an exercise price of $21.57.

Tyra Biosciences' CEO, Todd Harris, was granted 390,000 stock options on August 14, 2024, according to a Form 4 filing with the SEC.

Alan Fuhrman, CFO of Tyra Biosciences, reports the acquisition of stock options in the company.

Director Gilla Kaplan exercised stock options and disposed of shares of Tyra Biosciences on June 13, 2024.

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, reported the sale of company stock on June 7 and June 10, 2024, according to a Form 4 filing with the SEC.

RA Capital Management and related entities report acquisition of stock options in Tyra Biosciences, Inc. pursuant to a non-employee director compensation program.

Director Jake Simson of Tyra Biosciences, Inc. was granted stock options for 18,600 shares on May 29, 2024, according to a Form 4 filing.

Director Rehan Verjee acquired 18,600 stock options in Tyra Biosciences, Inc. on May 29, 2024, according to a Form 4 filing.

Director Siddarth Subramony acquired stock options in Tyra Biosciences, Inc. on May 29, 2024, according to a Form 4 filing.

Director Gilla Kaplan acquired 18,600 stock options in Tyra Biosciences, Inc. on May 29, 2024, according to a Form 4 filing.

Director Robert J. More acquired stock options in Tyra Biosciences, Inc. on May 29, 2024, as part of the Non-Employee Director Compensation Program.

Director Nina S. Kjellson acquired 18,600 stock options in Tyra Biosciences, Inc. on May 29, 2024, as part of the Non-Employee Director Compensation Program.

Director Susan Moran acquired 37,200 shares of Tyra Biosciences common stock through an option grant on May 7, 2024, at an exercise price of $17.94.

Stephen Michael Rothenberg, a director at Tyra Biosciences, acquired 37,200 shares of common stock through an option grant on May 7, 2024.

Alan Fuhrman, CFO of Tyra Biosciences, reports acquiring 932 shares of common stock through the company's Employee Stock Purchase Plan.

Hiroomi Tada, Chief Medical Officer of Tyra Biosciences, acquired 1,968 shares of common stock through the company's Employee Stock Purchase Plan on March 15, 2024.

Todd Harris, President and CEO of Tyra Biosciences, acquired 1,880 shares of common stock through the company's Employee Stock Purchase Plan on March 15, 2024.

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, sold 200 shares of common stock on March 11, 2024, at a price of $20 per share.

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, sold shares of common stock on March 6 and 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, sold shares of common stock between March 1 and March 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Daniel Bensen, Chief Operating Officer of Tyra Biosciences, sold shares of common stock over three days in late February under a pre-arranged Rule 10b5-1 trading plan.